Skip to main content

NVS

Stock
Health Care
Drug Manufacturers - General

Performance overview

NVS Price
Price Chart

Forward-looking statistics

Beta
0.49
Risk
18.66%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees89K
Market cap$214.9B

Fundamentals

Enterprise value$261.3B
Revenue$53.2B
Revenue per employee
Profit margin24.16%
Debt to equity81.32

Security info

ExchangeNyse American
Type of shareADR
Earnings per share (EPS)$6.38
Dividend per share$15.48
Revenue per share$26.62
Avg trading volume (30 day)$151M
Avg trading volume (10 day)$162M
Put-call ratio

Macro factor sensitivity

Growth-0.8
Credit+2.3
Liquidity+0.4
Inflation-2.4
Commodities-0.5
Interest Rates-0.9

Valuation

Dividend yield12.70%
PEG Ratio14.48
Price to sales4.58
P/E Ratio14.48
Enterprise Value to Revenue4.91
Price to book6.22

Upcoming events

Next earnings dayJuly 17, 2025
Next dividend day
Ex. dividend dayMarch 12, 2025

News

Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025

J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.

Zacks Investment Research (July 21, 2025)
Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data

With retail sales rebounding and Wall Street gaining, low-leverage stocks like NVS, RMD, WAB, ESLT and INGR offer scope for upside.

Zacks Investment Research (July 18, 2025)
Tariffs are an overhang on pharma sector, but we will comeback, says Novartis CEO Vas Narasimhan

Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss tariffs on pharmaceuticals, second quarter earnings and outlook on the pharma sector.

CNBC Television (July 17, 2025)
Novartis raises outlook on strong second-quarter sales

CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.

CNBC International TV (July 17, 2025)
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise

Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio. The Swiss pharma firm is looking to shift reliance away from its Entresto heart failure therapy.

CNBC (July 17, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free